Vanguard Group Inc. Sells 291,724 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Vanguard Group Inc. reduced its holdings in Amphastar Pharmaceuticals by 10.7%, now owning 2,422,904 shares valued at approximately $70.24 million.
• Several institutional investors have increased their stakes in Amphastar, highlighting a significant interest in the company, which has a total of 65.09% of its stock owned by institutional investors.
• Analysts have mixed ratings on Amphastar Pharmaceuticals, with a consensus price target of $31.50 and two analysts giving a 'buy' rating.

Vanguard Group Inc. lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 10.7% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,422,904 shares of the company's stock after selling 291,724 shares during the quarter. Vanguard Group Inc. owned approximately 5.10% of Amphastar Pharmaceuticals worth $70,240,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in AMPH. Signaturefd LLC boosted its stake in shares of Amphastar Pharmaceuticals by 147.7% during the first quarter. Signaturefd LLC now owns 872 shares of the company's stock valued at $25,000 after purchasing an additional 520 shares during the period. IFP Advisors Inc purchased a new stake in Amphastar Pharmaceuticals in the first quarter worth $34,000. GF Fund Management CO. LTD. purchased a new stake in Amphastar Pharmaceuticals in the fourth quarter worth $38,000. GAMMA Investing LLC lifted its stake in Amphastar Pharmaceuticals by 46.6% in the first quarter. GAMMA Investing LLC now owns 1,333 shares of the company's stock worth $39,000 after acquiring an additional 424 shares during the period. Finally, Tower Research Capital LLC TRC lifted its stake in Amphastar Pharmaceuticals by 43.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company's stock worth $43,000 after acquiring an additional 348 shares during the period. Hedge funds and other institutional investors own 65.09% of the company's stock.

Amphastar Pharmaceuticals Stock Up 1.2%

AMPH traded up $0.36 during trading on Friday, reaching $30.62. The stock had a trading volume of 290,925 shares, compared to its average volume of 638,844. The stock's 50 day moving average is $24.60 and its two-hundred day moving average is $25.79. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of 11.47 and a beta of 0.76. Amphastar Pharmaceuticals, Inc. has a one year low of $20.39 and a one year high of $53.96.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price target for the company in a research note on Tuesday, August 12th. Bank of America raised their price target on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research note on Tuesday. Wells Fargo & Company dropped their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. JPMorgan Chase & Co. reaffirmed a "neutral" rating and issued a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Finally, Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a research note on Friday, August 8th. Two equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of "Hold" and an average price target of $31.60.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.